Doxorubicin hydrochloride is a non-periodic specific antineoplastic drug with a broad antineoplastic spectrum. It can be used clinically in breast cancer, lung cancer, lymphoma, ovarian cancer and other cancers. As a second-line antineoplastic drug, doxorubicin is the first choice for drug resistance.
Doxorubicin hydrochloride inhibits DNA topoisomerase II by embedding and inhibiting the interaction between polymer biosynthesis and DNA. Doxorubicin hydrochloride prevents the closure of DNA double helix, thus destroying the replication of DNA strands. By embedding, doxorubicin can also act on transcriptionally active chromatin, leading to histone changes. The results showed that DNA damage response, epigenome and transcriptome were uncontrolled in the cells acted by doxorubicin.
Doxorubicin hydrochloride is used in the treatment of acute lymphoblastic leukemia, acute granulocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, breast cancer, lung cancer and ovarian cancer.